Are Peptides Legal in Missouri? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Missouri as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Missouri attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Missouri statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Missouri has scheduled or banned on its own. The Missouri Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Missouri at a glance

State controlled-substances law: RSMo chapters 195 and 579, the Comprehensive Drug Control Act; schedules at RSMo § 195.017 (revisor.mo.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (RSMo § 195.017 (Schedule III)) (revisor.mo.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: No GLP-1-specific statement from the Missouri Board of Pharmacy was found. Its 2025 Pharmacy Practice Guide restates the general rules: Missouri law prohibits compounding preparations that are commercially available or essentially copies of them, and a bulk drug substance without a USP or NF monograph that is not a component of an approved drug cannot be used unless it is on the FDA 503A bulks list (2025) (pr.mo.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes, with statutory conditions. RSMo § 191.1146 lets a physician-patient relationship be established by telemedicine if the standard of care does not require an in-person encounter, and requires any online questionnaire to be reviewed by the treating professional and to contain enough to substitute for an in-person evaluation. RSMo § 334.108 requires a reliable history and, where the standard of care requires, a physical examination before prescribing by telemedicine or the internet. Both sections were amended with effect from 28 August 2026, so check the current text. (revisor.mo.gov)
State-level enforcement, 2023 to 2026: None found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Missouri, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Missouri:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Missouri. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Missouri law adds

Missouri's controlled-substances law (RSMo chapters 195 and 579, the Comprehensive Drug Control Act; schedules at RSMo § 195.017) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (revisor.mo.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Missouri's schedules or in a Missouri-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Missouri's schedules list anabolic steroids related to testosterone; human growth hormone, somatropin and chorionic gonadotropin do not appear in any schedule, so only the federal HGH statute applies. (RSMo § 195.017 (Schedule III)) (revisor.mo.gov)

Compounded semaglutide and tirzepatide

2025. No GLP-1-specific statement from the Missouri Board of Pharmacy was found. Its 2025 Pharmacy Practice Guide restates the general rules: Missouri law prohibits compounding preparations that are commercially available or essentially copies of them, and a bulk drug substance without a USP or NF monograph that is not a component of an approved drug cannot be used unless it is on the FDA 503A bulks list. (pr.mo.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Missouri medical board guidance specific to peptide therapy was located. A Missouri prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Missouri

RSMo § 579.015 criminalises knowing possession of a controlled substance only; no Missouri offence for an individual possessing an unscheduled research peptide was found, and the compounding and bulk-substance rules bind pharmacies and prescribers rather than consumers. (revisor.mo.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Missouri is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes, with statutory conditions. RSMo § 191.1146 lets a physician-patient relationship be established by telemedicine if the standard of care does not require an in-person encounter, and requires any online questionnaire to be reviewed by the treating professional and to contain enough to substitute for an in-person evaluation. RSMo § 334.108 requires a reliable history and, where the standard of care requires, a physical examination before prescribing by telemedicine or the internet. Both sections were amended with effect from 28 August 2026, so check the current text. (revisor.mo.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Missouri law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Missouri

The Bureau found no Missouri-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. Missouri is not on the February 2025 multistate letter; in September 2026 its attorney general joined a 20-state letter to the National Security Council about Chinese-sourced GLP-1 ingredients, which is advocacy rather than enforcement. No healing arts board guidance on peptides or medspas was found.

Frequently asked questions

Is BPC-157 legal in Missouri?

Missouri has not scheduled BPC-157, so possessing it is not a Missouri offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Missouri?

Yes, with statutory conditions. RSMo § 191.1146 lets a physician-patient relationship be established by telemedicine if the standard of care does not require an in-person encounter, and requires any online questionnaire to be reviewed by the treating professional and to contain enough to substitute for an in-person evaluation. RSMo § 334.108 requires a reliable history and, where the standard of care requires, a physical examination before prescribing by telemedicine or the internet. Both sections were amended with effect from 28 August 2026, so check the current text. The Missouri Board of Pharmacy position on compounded versions: No GLP-1-specific statement from the Missouri Board of Pharmacy was found. Its 2025 Pharmacy Practice Guide restates the general rules: Missouri law prohibits compounding preparations that are commercially available or essentially copies of them, and a bulk drug substance without a USP or NF monograph that is not a component of an approved drug cannot be used unless it is on the FDA 503A bulks list.

Is HGH legal in Missouri?

Only with a valid prescription for an approved use. Missouri does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Missouri fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.